María Dolores López Abellán

Ms. María Dolores López Abellán


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ACAntonio Asensi Cantó
Antonio Asensi Cantó
MAMaría Dolores López Abellán
María Dolores López Abellán
VCVerónica Castillo-Guardiola
Verónica Castillo-Guardiola
AHAna María Hurtado
Ana María Hurtado
MMMónica Martínez-Penella
Mónica Martínez-Penella
PCPablo Conesa-Zamora
Pablo Conesa-Zamora
Growing evidence shows that nerves play an active role in cancer development and progression by altering crucial molecular pathways and cell functions. Conversely, the use of neurotropic drugs, such as tricyclic antidepressants (TCAs), may modulate these molecular signals with a therapeutic purpose based on a direct antitumoral effect and beyond the TCA use to treat neuropathic pain in oncology patients. In this review, we discuss the TCAs’ safety and their central effects against neuropathic pain in cancer, and the antitumoral effects of TCAs in in vitro and preclinical studies, as well as in the clinical setting. The current evidence points out that TCAs are safe and beneficial to treat neuropathic pain associated with cancer and chemotherapy, and they block different molecular pathways used by cancer cells from different locations for tumor growth and promotion. Likewise, ongoing clinical trials evaluating the antineoplastic effects of TCAs are discussed. TCAs are very biologically active compounds, and their repurposing as antitumoral drugs is a promising and straightforward approach to treat specific cancer subtypes and to further define their molecular targets, as well as an interesting starting point to design analogues with increased antitumoral activity.

Verified
Journal Article
Open access
PDF file
BABegoña Alburquerque-González
Begoña Alburquerque-González
FLFernando F. López-Calderón
Fernando F. López-Calderón
MAMaría Dolores López Abellán
María Dolores López Abellán
ÁEÁngel Esteban-Gil
Ángel Esteban-Gil
JGJosé García-Solano
José García-Solano
PCPablo Conesa-Zamora
Pablo Conesa-Zamora
Serrated adenocarcinoma (SAC) is a tumor recognized by the WHO as a histological subtype accounting for around 9% of colorectal carcinomas. Compared to conventional carcinomas, SACs are characterized by a worse prognosis, weak development of the immune response, an active invasive front and a frequent resistance to targeted therapy due to a high occurrence of KRAS or BRAF mutation. Nonetheless, several high-throughput studies have recently been carried out unveiling the biology of this cancer and identifying potential molecular targets, favoring a future histologically based treatment. This review revises the current evidence, aiming to propose potential molecular targets and specific treatments for this aggressive tumor.

8 January 2021 in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
Verified
Journal Article
Open access
PDF file
LRLuis García De Guadiana Romualdo
Luis García De Guadiana Romualdo
CRCarlos Rodríguez Rojas
Carlos Rodríguez Rojas
VAVerónica Ramos Arenas
Verónica Ramos Arenas
RGRubén Cárdenas Gámez
Rubén Cárdenas Gámez
MAMaría Dolores López Abellán
María Dolores López Abellán
MMMercedes González Morales
Mercedes González Morales
Objectives: Paracetamol intoxication is one of the causes of elevated procalcitonin concentrations unrelated to infection. We report a case series of two patients intoxicated with paracetamol whose laboratory data revealed a significant elevation of serum procalcitonin concentrations without clinical, radiological and/or biological evidence of infection. The underlying mechanism by which paracetamol triggers an increase in procalcitonin concentrations is still unclear. Case presentation: We report two cases of paracetamol intoxication. Both patients were admitted to the Emergency Department (ED) and subsequently transferred to the Intensive Care Unit (ICU). The patients exhibited elevated procalcitonin levels during the first hours of admission without clinical and/or microbiological evidence of infection that could explain such increase. Notably, only Case 1 developed liver injury, with alterations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and esterified bilirubin concentrations, which were not observed in Case 2. Conclusions: The two patients showed elevated procalcitonin concentrations resulting from paracetamol intoxication, although only a patient exhibited signs of liver injury. These findings suggest that increased procalcitonin levels induced by a paracetamol overdose cannot be fully explained by hepatocyte injury alone, but other mechanisms involving other organs and tissues may also be associated. In any case, although this mechanism is not well understood, it is important to be aware of this limitation when using procalcitonin as a biomarker of infection in patients intoxicated with paracetamol.